History RepeatsFor those who like charts, there are certain months when ONCY pps rises significantly, usually in expectation of great data/announcements around the time of a particular conference.
Why do I expect the price to stagenate or fall back to $1.10-$1.25 lows again by early next year..? Well why did ONCY do a financing so cheaply compared to the highs of 2023... probably because management was well aware there would be no other real inflection points to keep the price rising. They have sold stock into highs for as long as I've been invested. If Matt thought there was truly earth shattering news to announce, he would have held off on the financing... so I conclude that for the next 3-5 months, this is dead in the water...
I would also expect (hope) another decent run in late April/May, before the announcement of start of Phase III. Wouldn't it be nice for the pps to get above $3 and keep going for once.
Although why ONCY cannot start the Phase III with the combo they told us about in June already is beyond me. They shuld have amended the study protocol by now, and had that agreed by FDA/ ethics committees.
Also, IND213 confirmed statistically, that the Pela Triplet is better than Pax alone. So they won't be running a phase III with a CPI anymore for that indication... I do not believe they are waiting for Bracelet-1 to mature (that was the argument for the failed Phase III head and neck trial, and look where that ended up ). Pure speculation on my part, but I think ONCY will pull a fast one, and trash the mBC Phase III trial, and focus on two shots at goal with different combos for Panc.
Whilst these clowns have been stating they are advancing towards a registrational study for 6 years straight (overtaken by the occasional snail), I think the panc trial probabcly could be ONCY's saviour. By mid 2025, it will finally be clear if this works or not... Whatever the pumpers claim, this is STILL a risky investment.
any thoughts ?